×

Biotech and Pharmaceuticals Pharmaceuticals

  • Raman Singh, CEO at Mundipharma, says more education is needed in developing countries to understand how to use pain medications in diseases like cancer.

  • An official says Nevada doesn't plan to return one of the drugs obtained for use in an upcoming execution, despite a demand by pharmaceutical company Pfizer that its drugs not be used for lethal injections. The Nevada letter, obtained by The Associated Press, seeks the return of the sedative diazepam or the opioid painkiller fentanyl if it was manufactured by...

  • A Nevada prisons official said Friday the state is refusing pharmaceutical company Pfizer's demand to return a drug it manufactured and not use it in a planned lethal injection execution. Nevada received a letter Oct. 4 similar to one received by officials in Nebraska and reported by the Omaha World-Herald, Nevada Department of Corrections spokeswoman...

  • Drug companies search for non-addictive ways to treat pain

    CNBC's Meg Tirrell reports drug companies are looking to genetics for clues about developing a whole new class of pain medicines.

  • Nov 16- The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, such as requiring health insurers to pass on discounts to consumers. To help combat overprescription and abuse of addictive painkillers, the U.S. Centers for Medicare and Medicaid...

  • Nov 16- The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, including requiring health insurers to pass on discounts to consumers. To help combat overprescription and abuse of addictive painkillers, the U.S. Centers for Medicare and...

  • Cramer applauds Abbott CEO Miles White for his value creation and leadership

    Jim Cramer zoomed in on the track record of Abbott CEO Miles White, who has transformed the pharmaceutical company since he took over in 1999.

  • Jim Cramer on the set of Mad Money.

    Jim Cramer said the old-school tech company could be ready to make a comeback, despite the moves of Warren Buffett.

  • Cramer applauds Miles White, Abbott CEO

    Jim Cramer zoomed in on the track record of Abbott CEO Miles White, who has transformed the pharmaceutical company since he took over in 1999.

  • Miles D. White, CEO, Abbott

    Jim Cramer zoomed in on the track record of Abbott CEO Miles White, who has transformed the company since he took over in 1999.

  • *FDA's Hemlibra approval comes with blood clot warning. ZURICH, Nov 16- The U.S. Food and Drug Administration on Thursday approved Roche's Hemlibra, a new medicine for hemophilia A that the Swiss drugmaker is counting on to help to offset eroding sales of older medicines going off patent. But the FDA slapped Roche's medicine with a black box warning, the most...

  • *FDA's Hemlibra approval comes with blood clot warning. ZURICH, Nov 16- The U.S. Food and Drug Administration on Thursday approved Roche's Hemlibra, a new medicine for haemophilia A that the Swiss drugmaker is counting on to help to offset eroding sales of older medicines going off patent. But the FDA slapped Roche's medicine with a black box warning, the most...

  • Cramer Remix: Warren Buffett selling IBM could be a sign it’s on the cusp of a turn

    Jim Cramer said the old-school tech company could be ready to make a comeback, despite the moves of Warren Buffett.

  • BOSTON, Nov 16- The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty on Thursday to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray to treat pain in cancer patients. John Kapoor, who stepped down as Insys' chief executive officer and chairman in January but remains its majority...

  • The Food and Drug Administration laid out a strategy for regulating cell-based medicine, including hundreds of private clinics that have opened across the nation in the last decade. They can cost $5,000 to $50,000, but there's little research that such procedures are safe or effective. FDA officials said they will focus their enforcement efforts on "bad...

  • *FDA's Hemlibra approval comes with blood clot warning. ZURICH, Nov 16- The U.S. Food and Drug Administration on Thursday approved Roche's Hemlibra, a new medicine for haemophilia A that the Swiss drugmaker is counting on to help to offset eroding sales of older medicines going off patent. But the FDA slapped Roche's medicine with a black box warning for blood...

  • *FDA's Hemlibra approval comes with blood clot warning. ZURICH, Nov 16- The U.S. Food and Drug Administration on Thursday approved Roche's Hemlibra, a new medicine for hemophilia A that the Swiss drugmaker is counting on to help to offset eroding sales of older medicines going off patent. But the FDA slapped Roche's medicine with a black box warning for blood clots,...

  • BOSTON, Nov 16- The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray intended for cancer patients. John Kapoor, who stepped down as Insys' chief executive officer and chairman in January but remained its majority shareholder, entered his...

  • *FDA's Hemlibra approval comes with blood clot warning. ZURICH, Nov 16- The U.S. Food and Drug Administration on Thursday approved Roche's Hemlibra, a new medicine for haemophilia A that the Swiss drugmaker is counting on to help to offset eroding sales of older medicines going off patent. But the FDA slapped Roche's medicine with a black box warning for blood...

  • *FDA's Hemlibra approval comes with blood clot warning. ZURICH, Nov 16- The U.S. Food and Drug Administration on Thursday approved Roche's Hemlibra, a new medicine for hemophilia A that the Swiss drugmaker is counting on to help to offset eroding sales of older medicines going off patent. But the FDA slapped Roche's medicine with a black box warning for blood clots,...